Skip to main content
Log in

In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand

  • Original article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract.

The aim of this study was to assess the utility of a radioimmunoconjugate containing a lead radionuclide for therapy and scintigraphy applications. The radioimmunoconjugate evaluated consisted of a bifunctional DOTA ligand and monoclonal antibody (MAb) B72.3 using athymic mice bearing LS-174T tumors, human colon carcinoma xenografts. In the studies reported here, the lead-203-DOTA complex itself was first demonstrated to have in vivo stability. MAb B72.3 was then conjugated with the DOTA ligand and labeled with 203Pb, and the immunoreactivity of B72.3 was maintained. The localization of the radioimmunoconjugate to tumor tissue and other select organs paralleled that of DOTA-125I-B72.3, suggesting a similar metabolic pattern of the two radioimmunoconjugates. Thus, the DOTA-metal complex does not alter the behavior of the radioimmunoconjugate. Tumor localization of the 203Pb-DOTA-B72.3 conjugate was demonstrated with biodistribution studies as well as immunoscintigraphy studies. Such data highlight the stability of a lead radionuclide in the DOTA ligand. The suitability of this chelation chemistry for labeling radioimmunoconjugates with a lead radionuclide now makes its application in nuclear medicine a feasible proposition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received 25 October 1997 and in revised form 23 January 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milenic, D., Roselli, M., Brechbiel, M. et al. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. Eur J Nucl Med 25, 471–480 (1998). https://doi.org/10.1007/s002590050246

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002590050246

Navigation